European regulators have reviewed safety data on semaglutide-based medications, including Ozempic and Wegovy, after reports linking them to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which can affect vision. Agencies say the overall risk remains low but are monitoring cases and updating guidance where needed. Health experts continue to stress that patients should discuss benefits, risks, and alternatives with their doctors before starting or stopping treatment.
Weight loss drugs like Ozempic and Wegovy linked to sudden blindness
